SYRE vs. VKTX, AXSM, KRYS, TGTX, OGN, SRRK, ALVO, RARE, ADMA, and BHVN
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), TG Therapeutics (TGTX), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs.
Spyre Therapeutics (NASDAQ:SYRE) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Viking Therapeutics received 604 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 79.92% of users gave Viking Therapeutics an outperform vote.
Viking Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spyre Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
Viking Therapeutics' return on equity of -12.73% beat Spyre Therapeutics' return on equity.
In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 13 articles in the media. Spyre Therapeutics' average media sentiment score of 0.44 beat Viking Therapeutics' score of 0.44 indicating that Spyre Therapeutics is being referred to more favorably in the media.
Spyre Therapeutics presently has a consensus target price of $54.83, suggesting a potential upside of 165.92%. Viking Therapeutics has a consensus target price of $106.75, suggesting a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Spyre Therapeutics.
Summary
Viking Therapeutics beats Spyre Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 1/20/2025 by MarketBeat.com Staff
Free SYRE Stock Alerts